Greehey CCRI Archives
Open Access Government: Developing novel therapies for childhood cancers (Houghton)
September 19, 2023Dr Peter J Houghton from Greehey Children’s Cancer Research Institute discusses the obstacles in developing new treatments for childhood cancers and new approaches in preclinical testing. In my previous article for Open Access Government, I focused on …
Bioinformatics Advances: DepLink: an R Shiny app to systematically link genetic and pharmacologic dependencies of cancer (Zheng, Houghton, & Chen Labs)
June 27, 2023Tapsya Nayak, Li-Ju Wang, Michael Ning, Gabriela Rubannelsonkumar, Eric Jin, Siyuan Zheng, Peter J Houghton, Yufei Huang, Yu-Chiao Chiu, Yidong Chen Abstract Motivation Large-scale genetic and pharmacologic dependency maps are generated to reveal genet …
Panneerdoss Subbarayalu, PhD, to receive NIH, NCI R21 Grant, “Targeting the RNA Modifying Enzyme ALKBH5 in Medulloblastoma
June 5, 2023Project Title: Targeting the RNA modifying enzyme ALKBH5 in Medulloblastoma Principal Investigator: Panneerdoss Subbarayalu Co-Investigators: Manjeet Rao, PhD, Andrew Brenner, MD, PhD., Peter Houghton, PhD. Funding Agency: National Institutes of Health …
ELife: Defining function of wild-type and three patient specific TP53 mutations in a zebrafish model of embryonal rhabdomyosarcoma (Ignatius Lab, Houghton Lab, Libich Lab, Chen, Tomlinson)
June 2, 2023Jiangfei Chen Kunal Baxi Amanda E Lipsitt Nicole Rae Hensch Long Wang Prethish Sreenivas Paulomi Modi Xiang Ru Zhao Antoine Baudin Daniel G Robledo Abhik Bandyopadhyay Aaron Sugalski Anil K Challa Dias Kurmashev Andrea R Gilbert Gail E Tomlinson Peter …
Cell Reports: EWSR1 Maintains Centromere Identity (Kitagawa & Houghton labs)
May 30, 2023Risa Kitagawa 1, Yohei Niikura 1 2, Argentina Becker 1 3, Peter J. Houghton 1, Katsumi Kitagawa 1 4 Highlights EWSR1 is required to maintain CENP-A at the centromere in interphase cells EWSR1 binds to CENP-A through the SYGQ2 region, important for phas …
Cancer Research: Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time (Houghton)
March 15, 2023Tuyen Duong;Thanh Nguyen; Yan Wang; Tuyen N. Bui; Rossana Lazcano; Davis R. Ingram; Min Yi; Varshini Vakulabharanam; Linjie Luo; Marc A. Pina; Cansu Karakas ; Mi Li; Nicole M. Kettner; Neeta Somaiah; Peter J. Hougton; Osama Mawlawi; Alexander J. Laz …
Precision Oncology News: Lantern Pharma Preparing IND for Synthetic Lethality Program With FDA Feedback
January 18, 2023Jan 17, 2023 | staff reporter NEW YORK – Lantern Pharma on Tuesday said it received feedback from the US Food and Drug Administration that it will use to submit an investigational new drug application for LP-184. The company furthe …
Molecular Cancer Theraputics: Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma (Ignatius, Vaseva, Houghton Labs)
January 3, 2023Nicole R. Hensch, Kathryn Bondra, Long Wang, Prethish Sreenivas, Xiang R. Zhao, Paulomi Modi, Angelina V. Vaseva, Peter J. Houghton, Myron S. Ignatius Abstract In fusion-negative rhabdomyosarcoma (FN-RMS), a pediatric malignancy with skeletal muscle ch …
Nature Communications: Genomic disparities between cancers in adolescent and young adults and in older adults (Wang, Langevin, Houghton, & Zheng)
December 6, 2022Xiaojing Wang, Anne-Marie Langevin, Peter J. Houghton & Siyuan Zheng Cancers cause significant mortality and morbidity in adolescents and young adults (AYAs), but their biological underpinnings are incompletely understood. Here, we analyze clinical …
Business Wire: Lantern Pharma to Host Virtual KOL Webinar on the Treatment of Pediatric Cancers During Childhood Cancer Awareness Month, featuring Peter Houghton, Ph.D.
September 20, 2022Webinar to be hosted on Thursday, Sept. 22, 2022, at 12:00 p.m. ET, register here. Dr. Houghton will discuss challenges in drug development for pediatric cancers and preliminary results from Lantern’s drug candidates in preclinical pediatric cancer mod …
-
Page 1 out of 12
- Next